Pyrrolotriazine kinase inhibitors

US7534792B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Mark D. Wittman · Cheshire, US
• Harold Mastalerz · Guilford, US
• Kurt Zimmermann · Durham, US
• Mark G. Saulnier · Haddam, US
• Upender Velaparthi · Princeton Junction, US
• Dolatrai M. Vyas · Fayetteville, US
• Guifen Zhang · Wallingford, US
• Walter Lewis Johnson · Waterbury, US
• David B. Frennesson · Naugatuck, US
• Xiaopeng Sang · Glastonbury, US
• Peiying Liu · Madison, US
• David R. Langley · Meriden, US

Key dates

• Filing date: Jul 5, 2007
• Grant date: May 19, 2009
• Expiry date: Jul 5, 2027

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.